The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
EV-203: Phase 2 trial of enfortumab vedotin in patients with previously treated advanced urothelial carcinoma in China.
 
Siming Li
No Relationships to Disclose
 
Yanxia Shi
No Relationships to Disclose
 
Haiying Dong
No Relationships to Disclose
 
Hongqian Guo
No Relationships to Disclose
 
Yue Li
Employment - Astellas Investment China
 
Haishan Kadeerbai
Employment - Astellas Investment China
 
Chenming Xu
Employment - Astellas Investment China
 
Eric Kim
Employment - Seagen
Stock and Other Ownership Interests - Zogenix
Travel, Accommodations, Expenses - Merck
 
Sue Lee
Employment - Astellas Pharma
 
Seema Rao Gorla
Employment - Astellas Pharma
Research Funding - Astellas Pharma
Travel, Accommodations, Expenses - Astellas Pharma
 
Jun Zhang
No Relationships to Disclose
 
Jun Guo
Consulting or Advisory Role - Bayer; MSD; Novartis; Oriengene; Pfizer; Roche; Shanghai Junshi BioSciences; Simcere
 
Xinan Sheng
Speakers' Bureau - BeiGene; Junshi Pharmaceuticals; Novartis; Pfizer; RemeGen